Skip to content

Effects of oral nutritional supplementation on the occurrence of sarcopenia during preoperative neoadjuvant chemotherapy and short-term postoperative complications in gastric cancer patients

Effects of oral nutritional supplementation on the occurrence of sarcopenia during preoperative neoadjuvant chemotherapy and short-term postoperative complications in gastric cancer patients: a prospective, randomized, controlled, single center, and blind clinical study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076717
Enrollment
Unknown
Registered
2023-10-17
Start date
2023-10-17
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Experimental group:Add oral nutrition preparations to the normal diet
Control group:General diet and nutrition counseling for patients

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion Criteria (1) Age: 18-80 years old; (2) West China Hospital of Sichuan University was diagnosed with gastric adenocarcinoma, (3) After laparoscopic exploration, it was confirmed that it was locally advanced gastric cancer (cT3-4a, N-/+, M0), and decided to receive preoperative neoadjuvant chemotherapy. (4) The therapist has clear consciousness, can eat normally by mouth, and has no complications such as perforation, bleeding, or obstruction. (5) Those who understand the purpose and content of the research and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 2. Exclusion Criteria (1) Simultaneous or accompanied malignant tumours of other tissues and organs; (2) hypersensitivity to selected nutritional preparations; (3) There is an uncontrolled mental illness that is unable to cooperate or is unwilling to participate in the trial; (4) Acute and chronic obstruction of the digestive tract (including pyloric obstruction). (5) Short bowel syndrome; (6) Inflammatory bowel disease, chronic constipation or diarrhoea, pregnancy; (7) The patient has abnormal liver and kidney function (alanine aminotransferase ALT= 2 times the upper limit of normal value; Total bilirubin Tbil = 2 times the upper limit of normal value; creatinine Cr =2 times the upper limit of normal); (8) The patient has hypothyroidism or hyperthyroidism;

Design outcomes

Primary

MeasureTime frame
Incidence of sarcopenia after neoadjuvant chemotherapy;

Secondary

MeasureTime frame
Overall postoperative short-term complication rate;

Countries

China

Contacts

Public ContactWen Zhuang

West China Hospital, Sichuan University

zw4794@163.com+86 189 8060 1497

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026